Core Viewpoint - *ST Dongtong's actual controller and chairman, Huang Yongjun, has been investigated by the China Securities Regulatory Commission (CSRC) for suspected violations of information disclosure laws, which may lead to significant legal consequences for the company [2][4]. Company Operations - The company has stated that its production and operations are currently normal and that the investigation will not affect its regular business activities [4]. - *ST Dongtong has committed to strictly adhering to regulatory requirements for information disclosure during the ongoing investigation [4]. Regulatory Issues - On April 14, *ST Dongtong was already under investigation by the CSRC for suspected false reporting of financial data in regular reports, which could lead to mandatory delisting if significant violations are confirmed [4]. - The company received a negative internal control audit report from Beijing Dehao International Accounting Firm, indicating serious internal control issues [5]. Financial Performance - Since 2022, *ST Dongtong has been continuously reporting losses, with a net profit of -0.31 billion for the latest reporting period, reflecting a year-on-year increase in losses of 58.12% [6][7]. - The total revenue for the latest period was 1.34 billion, showing a year-on-year increase of 77.41% [7]. Market Position - As of August 6, *ST Dongtong's stock price was 5.68 yuan per share, with a total market capitalization of 3.2 billion [8][9].

Core Viewpoint - The company *ST Dongtong faces significant risks of forced delisting due to ongoing investigations by the China Securities Regulatory Commission (CSRC) regarding information disclosure violations by its actual controller and chairman, Huang Yongjun [1][3]. Group 1: Regulatory Actions - The actual controller Huang Yongjun has been formally investigated by the CSRC for suspected violations of information disclosure laws, marking the second investigation of the company and its core personnel within the year [1]. - The company previously disclosed on April 14 that it was under investigation for suspected false reporting of financial data, which could lead to forced delisting if confirmed by the CSRC [1][2]. Group 2: Financial Performance - In the 2024 annual report, *ST Dongtong reported a revenue of 758 million yuan, a year-on-year increase of 36.09%, but incurred a net loss of 576 million yuan [2]. - For the first quarter of 2025, the company achieved a revenue of 134 million yuan, with a net loss of approximately 30.54 million yuan [2]. Group 3: Audit Opinions - The 2024 annual report received an audit opinion of "unable to express an opinion," and the internal control was given a negative opinion, triggering delisting risk warnings and other risk warnings from the Shenzhen Stock Exchange [2]. - As a result of these audit findings, the company's stock was subject to delisting risk warnings and was renamed from "Dongfang Tong" to "*ST Dongtong" starting May 6 [2]. Group 4: Operational Status - Despite the ongoing investigations, the company asserts that its production and operational activities remain normal and that it will comply with regulatory requirements for information disclosure during the investigation period [3].

Core Viewpoint - *ST Dongtong's chairman Huang Yongjun is under investigation by the China Securities Regulatory Commission (CSRC) for suspected violations of information disclosure laws [1][3]. Group 1: Investigation Details - On August 6, *ST Dongtong announced that its actual controller and chairman Huang Yongjun received a notice of investigation from the CSRC due to suspected violations of information disclosure laws [3]. - The company stated that its production and operations are currently normal and that the investigation will not affect its regular business activities [3][4]. - The CSRC had previously initiated an investigation on April 14 for suspected false records in periodic reports and financial data [3]. Group 2: Internal Control Issues - *ST Dongtong has significant internal control issues, as indicated by a negative internal control audit report issued by Beijing Dehao International Accounting Firm [6]. - Following this, the company's stock was placed under delisting risk warning and other risk warnings starting May 6, with its stock name changed from "Dongfang Tong" to "*ST Dongtong" [6]. Group 3: Financial Performance - Since 2022, *ST Dongtong has been continuously reporting losses [7]. - As of August 6, the stock price of *ST Dongtong was reported at 5.68 yuan per share, with a total market capitalization of 3.2 billion yuan [8].

Core Viewpoint - *ST Dongtong's chairman Huang Yongjun is under investigation by the China Securities Regulatory Commission (CSRC) for suspected violations of information disclosure laws [2][3]. Group 1: Investigation Details - On August 6, *ST Dongtong announced that its actual controller and chairman Huang Yongjun received a notice of investigation from the CSRC due to suspected violations of information disclosure laws [3]. - The investigation is ongoing, and the company has not yet received any conclusive opinions or decisions from the CSRC [5]. Group 2: Company Operations - *ST Dongtong stated that its production and operations are currently normal, and the investigation will not affect its regular business activities [5]. - The company is committed to fulfilling its information disclosure obligations as required by regulators [5]. Group 3: Financial Performance - As of March 31, 2025, *ST Dongtong reported total revenue of 1.34 billion, a year-on-year increase of 77.41% [7]. - The company has been experiencing continuous losses since 2022, with a net profit of -0.31 billion for the latest reporting period, reflecting a year-on-year increase in losses of 58.12% [7]. - The internal control audit report for 2024 was issued with a negative opinion, highlighting significant internal control issues [6]. Group 4: Stock Information - As of the close on August 6, *ST Dongtong's stock price was 5.68 yuan per share, with a total market capitalization of 3.2 billion [8].

Core Viewpoint - *ST Dongtong faces significant risks of forced delisting due to ongoing investigations by the China Securities Regulatory Commission (CSRC) regarding information disclosure violations by its actual controller and chairman, Huang Yongjun [2][4]. Group 1: Regulatory Actions - The actual controller Huang Yongjun has been formally investigated by the CSRC for suspected violations of information disclosure laws [2][4]. - This marks the second investigation of *ST Dongtong and its key personnel by the CSRC within the year, following an earlier investigation related to false financial reporting [2][3]. - The company has received a warning of potential forced delisting if the CSRC's findings confirm significant violations as per Shenzhen Stock Exchange regulations [2][3]. Group 2: Financial Performance - In the 2024 annual report, *ST Dongtong reported revenues of 758 million yuan, a year-on-year increase of 36.09%, but incurred a net loss of 576 million yuan [3]. - For the first quarter of 2025, the company achieved revenues of 134 million yuan, with a net loss of approximately 30.54 million yuan [3]. Group 3: Audit Opinions - The 2024 annual report received an audit opinion of "unable to express an opinion," and the internal control was given a negative opinion, triggering delisting risk warnings from the Shenzhen Stock Exchange [3]. - As a result of these audit findings, the company's stock was subjected to delisting risk warnings and other risk warnings, leading to a name change from "Dongfang Tong" to "*ST Dongtong" [3]. Group 4: Company Operations - Despite the ongoing investigations, *ST Dongtong asserts that its production and operational activities remain normal and unaffected [4]. - The company commits to cooperating with the CSRC's investigation and adhering to regulatory disclosure requirements [4].

证券代码：300379 证券简称：*ST 东通 公告编号：2025-076 北京东方通科技股份有限公司 关于实际控制人、董事长收到中国证券监督管理委员会 立案告知书暨风险提示的公告 （证监立案字 0142025031 号），因涉 嫌信息披露违法违规，根据《中华人民共和国证券法》《中华人民共和国行政处 罚法》等法律法规，中国证监会决定对其立案。 目前，公司生产经营情况一切正常，上述事项不会影响公司正常的生产经营 活动。立案调查期间，黄永军先生将积极配合中国证监会的相关调查工作，公司 将严格按照监管要求履行信息披露义务。 另外，公司于 2025 年 4 月 14 日披露了《关于公司收到中国证券监督管理委 员会立案告知书暨风险提示的公告》 （公告编号：2025-031）。因公司涉嫌定期报 告等财务数据存在虚假记载，被中国证监会立案。若后续经中国证监会行政处罚 认定的事实，触及《深圳证券交易所创业板股票上市规则（2025 年修订）》规定 的重大违法强制退市情形，公司股票将被实施重大违法强制退市。截至本公告披 露日，中国证监会的调查尚在进行中，公司尚未收到就上述立案事项的结论性意 见或决定。 北京东方通科技股份有限公司 ...

北京商报讯（记者 马换换 实习记者 李佳雪）8月6日晚间，*ST东通（300379）披露公告称，公司收到 实际控制人、董事长黄永军通知，其于当日收到证监会送达的《立案告知书》。因涉嫌信息披露违法违 规，证监会决定对其立案。 公告显示，*ST东通于2025年4月14日披露了《关于公司收到中国证券监督管理委员会立案告知书暨风 险提示的公告》。因公司涉嫌定期报告等财务数据存在虚假记载，被证监会立案。若后续经证监会行政 处罚认定的事实，触及重大违法强制退市情形，公司股票将被实施重大违法强制退市。截至公告披露 日，证监会的调查尚在进行中，公司尚未收到就上述立案事项的结论性意见或决定。 *ST东通表示，目前，公司生产经营情况一切正常，上述事项不会影响公司正常的生产经营活动。立案 调查期间，黄永军将积极配合证监会的相关调查工作，公司将严格按照监管要求履行信息披露义务。 交易行情显示，截至8月6日收盘，*ST东通股价报5.68元/股，总市值约31.69亿元。 ...

Group 1 - A total of 59 companies, executives, or shareholders have been investigated by the China Securities Regulatory Commission (CSRC) for violations of information disclosure as of August 5 this year [1] - Companies such as Dahua Intelligent, Knight Dairy, and Jiaotong University Anli have announced investigations since July, with Dahua Intelligent's stock dropping by 20% over three trading days following the announcement [1] - Violations of information disclosure include various situations such as illegal guarantees, fund occupation, changes in actual controllers, and share freezes, which are significant matters that listed companies must disclose [1] Group 2 - Tianmao Group was investigated by the CSRC for failing to disclose its 2024 annual report and 2025 Q1 report within the legal timeframe, leading to a delisting risk warning from the Shenzhen Stock Exchange [2] - Companies under investigation face risks of investor claims after administrative penalties, with most likely to receive orders for correction and fines, while some may face delisting risks due to financial fraud [2] - Stock prices of companies under investigation typically experience a short-term decline following the announcement of the investigation [2]

Core Viewpoint - Guangdong Jiaying Pharmaceutical Co., Ltd. is facing administrative penalties from the China Securities Regulatory Commission (CSRC) for failing to timely disclose related party transactions involving 220 million yuan [1][3][4] Group 1: Company Actions and Violations - Jiaying Pharmaceutical's chairman, Li Neng, is the actual controller of Hunan Yaojuneng Pharmaceutical Co., Ltd., which constitutes a related party [3] - From October 2024 to January 2025, Jiaying Pharmaceutical's subsidiary provided short-term loans to the related party, totaling 219.99 million yuan, which accounted for 28.83% of Jiaying Pharmaceutical's latest audited net assets [3][4] - The company did not follow the required procedures for related party transactions and failed to disclose these transactions in a timely manner [3][4] Group 2: Regulatory Response - The CSRC Guangdong Regulatory Bureau has determined that Jiaying Pharmaceutical's actions violate multiple provisions of the Securities Law, including failure to disclose related party transactions [4] - Proposed penalties include a warning and a fine of 1.5 million yuan for Jiaying Pharmaceutical, 1.6 million yuan for Li Neng, 1 million yuan for Yu Yongping, and 800,000 yuan for Shi Junping [5]

Core Viewpoint - The chairman of Jiaying Pharmaceutical, Li Neng, is facing penalties for misappropriating company funds shortly after taking office, highlighting governance issues within the company [1][2][3]. Group 1: Regulatory Actions - Jiaying Pharmaceutical received an administrative penalty notice from the Guangdong Securities Regulatory Bureau, with potential fines amounting to 1.5 million yuan for the company and additional fines for Li Neng and other responsible parties [1][3]. - The investigation revealed that from October 2024 to January 2025, Jiaying Pharmaceutical's subsidiary provided short-term loans to a company controlled by Li Neng, totaling 220 million yuan, which constituted 28.83% of the company's audited net assets at that time [1][3]. Group 2: Company Background - Jiaying Pharmaceutical, established in 2003 and listed in December 2007, specializes in the research, production, and sales of traditional Chinese medicine, with a focus on proprietary and patented products [8]. - The company has experienced frequent changes in its major shareholders over the years, with the most recent change occurring in 2023 when Dongfang Securities became the largest shareholder [8]. Group 3: Financial Performance - The company's financial performance has been lackluster, with net profits showing minimal growth over the past five years, including a net profit of only 15.4 million yuan in the first quarter of 2025, despite a nearly twofold increase compared to the previous year [1][8]. - From 2020 to 2024, Jiaying Pharmaceutical's net profits were 19.84 million yuan, 1.48 million yuan, 43.93 million yuan, 34.32 million yuan, and 20.61 million yuan, indicating overall stagnant performance [8][9].